Dr. Justin Annes will review the hPPGL Syndrome with particular focus on the underlying genetics basis and related tumor risks and the benefits/limitations of genetic testing and pre-symptomatic screening.
|
Monday
|
Tuesday
|
Wednesday
|
Thursday
|
Friday
|
Saturday
|
Sunday
|
|---|---|---|---|---|---|---|
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
|
0 events,
|
0 events,
|
0 events,
|
1 event,
Dr. Justin Annes will review the hPPGL Syndrome with particular focus on the underlying genetics basis and related tumor risks and the benefits/limitations of genetic testing and pre-symptomatic screening. |
0 events,
|
0 events,
|
0 events,
|
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
|
0 events,
|
0 events,
|
1 event,
Every GIST patient is unique based on their biology and what treatment to which they will potentially respond. Dr. Lori Rink, Fox Chase Cancer Center, and Dr. Inga-Marie Schaefer, Brigham & Women’s Hospital, are two researchers who are making discoveries in their respective laboratories to uncover the unique biomarkers in GIST that will be future drug targets. |
0 events,
|
0 events,
|
0 events,
|
0 events,
|